Discovering the pharmacodynamics of conolidine and cannabidiol using a cultured neuronal network based workflow

[1]  David John Adams,et al.  Mechanism of direct Cav2.2 channel block by the κ-opioid receptor agonist U50488H , 2016, Neuropharmacology.

[2]  Ayal B. Gussow,et al.  Inhibition of microRNA 128 promotes excitability of cultured cortical neuronal networks , 2016, Genome research.

[3]  E. Troncy,et al.  The emerging role of in vitro electrophysiological methods in CNS safety pharmacology. , 2016, Journal of pharmacological and toxicological methods.

[4]  D. Abrams,et al.  Integrating cannabis into clinical cancer care. , 2016, Current oncology.

[5]  G D C Mendis,et al.  Use of adaptive network burst detection methods for multielectrode array data and the generation of artificial spike patterns for method evaluation , 2016, Journal of neural engineering.

[6]  C. Bundgaard,et al.  A Multifaceted GABAA Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude) , 2015, Molecular Pharmacology.

[7]  Andrew Morton,et al.  Quantitative differences in developmental profiles of spontaneous activity in cortical and hippocampal cultures , 2014, Neural Development.

[8]  John Lowe,et al.  Faculty Opinions recommendation of Polypharmacology: challenges and opportunities in drug discovery. , 2014 .

[9]  J. Bajorath,et al.  Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.

[10]  Benjamin J. Whalley,et al.  Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders , 2014, Epilepsia.

[11]  G. Zamponi,et al.  Neuronal Voltage-Gated Calcium Channels: Structure, Function, and Dysfunction , 2014, Neuron.

[12]  Andrew F M Johnstone,et al.  Burst and principal components analyses of MEA data for 16 chemicals describe at least three effects classes. , 2014, Neurotoxicology.

[13]  R. Turnaturi,et al.  The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures , 2013, Neuropharmacology.

[14]  Michael C. Hout,et al.  Multidimensional Scaling , 2003, Encyclopedic Dictionary of Archaeology.

[15]  Kim-Anh Lê Cao,et al.  Independent Principal Component Analysis for biologically meaningful dimension reduction of large biological data sets , 2012, BMC Bioinformatics.

[16]  S. Meroueh,et al.  Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca2+ channel complex , 2011, Nature Medicine.

[17]  Monica Hoyos Flight.  Analgesia: Flower power , 2011, Nature Reviews Drug Discovery.

[18]  L. Bohn,et al.  Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain. , 2011, Nature chemistry.

[19]  Andrew F M Johnstone,et al.  Microelectrode arrays: a physiologically based neurotoxicity testing platform for the 21st century. , 2010, Neurotoxicology.

[20]  R. Lewis,et al.  Analgesic ω-Conotoxins CVIE and CVIF Selectively and Voltage-Dependently Block Recombinant and Native N-Type Calcium Channels , 2010, Molecular Pharmacology.

[21]  Jason H. Moore,et al.  BIOINFORMATICS REVIEW , 2005 .

[22]  Scott M. Williams,et al.  challenges for genome-wide association studies , 2010 .

[23]  L. Landmesser,et al.  Characterization of Rhythmic Ca2+ Transients in Early Embryonic Chick Motoneurons: Ca2+ Sources and Effects of Altered Activation of Transmitter Receptors , 2009, The Journal of Neuroscience.

[24]  Gerald W. Zamponi,et al.  Role of voltage-gated calcium channels in ascending pain pathways , 2009, Brain Research Reviews.

[25]  Paolo Massobrio,et al.  A novel algorithm for precise identification of spikes in extracellularly recorded neuronal signals , 2009, Journal of Neuroscience Methods.

[26]  M. Connor,et al.  Inhibition of Recombinant Human T-type Calcium Channels by Δ9-Tetrahydrocannabinol and Cannabidiol* , 2008, Journal of Biological Chemistry.

[27]  Ethan B. Russo.  Cannabinoids in the management of difficult to treat pain , 2008, Therapeutics and clinical risk management.

[28]  R. Pertwee,et al.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .

[29]  R. Pertwee.  The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids : D 9-tetrahydrocannabinol , cannabidiol and D 9-tetrahydrocannabivarin , 2007 .

[30]  D. S. Weiss,et al.  Mechanism of action of benzodiazepines on GABAA receptors , 2006, British journal of pharmacology.

[31]  Peter Jonas,et al.  Hyperpolarization‐activated cation channels in fast‐spiking interneurons of rat hippocampus , 2006, The Journal of physiology.

[32]  C. Tränkle,et al.  Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[33]  Steve M. Potter,et al.  An extremely rich repertoire of bursting patterns during the development of cortical cultures , 2006, BMC Neuroscience.

[34]  V. Gribkoff,et al.  Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain. , 2005, Biochemical pharmacology.

[35]  G. Gross,et al.  Substance identification by quantitative characterization of oscillatory activity in murine spinal cord networks on microelectrode arrays , 2004, The European journal of neuroscience.

[36]  M. Chiappalone,et al.  Networks of neurons coupled to microelectrode arrays: a neuronal sensory system for pharmacological applications. , 2003, Biosensors & bioelectronics.

[37]  T. Yaksh,et al.  Localization of N-type Ca2+ channels in the rat spinal cord following chronic constrictive nerve injury , 2002, Experimental Brain Research.

[38]  Y. Matsuda,et al.  Effects of ablation of N- and R-type Ca2+ channels on pain transmission , 2002, Neuroscience Research.

[39]  S. Hatakeyama,et al.  Differential nociceptive responses in mice lacking the alpha(1B) subunit of N-type Ca(2+) channels. , 2001, Neuroreport.

[40]  Dong Kwan Kim,et al.  Altered Nociceptive Response in Mice Deficient in the α1B Subunit of the Voltage-Dependent Calcium Channel , 2001, Molecular and Cellular Neuroscience.

[41]  J. H. Moore,et al.  Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. , 2001, American journal of human genetics.

[42]  H. Saegusa,et al.  Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N‐type Ca2+ channel , 2001, The EMBO journal.

[43]  F O Ettinger,et al.  Flower power. , 2001, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[44]  G. Gross,et al.  Drug evaluations using neuronal networks cultured on microelectrode arrays. , 2000, Biosensors & bioelectronics.

[45]  E. Perez-Reyes,et al.  Nickel block of three cloned T-type calcium channels: low concentrations selectively block alpha1H. , 1999, Biophysical journal.

[46]  P. Ornstein,et al.  LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors , 1998, Neuropharmacology.

[47]  C. McBain,et al.  The hyperpolarization‐activated current (Ih) and its contribution to pacemaker activity in rat CA1 hippocampal stratum oriens‐alveus interneurones. , 1996, The Journal of physiology.

[48]  Christopher J. Evans,et al.  Morphine Activates Opioid Receptors without Causing Their Rapid Internalization* , 1996, The Journal of Biological Chemistry.

[49]  U. Misgeld,et al.  A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system , 1995, Progress in Neurobiology.

[50]  J. Luebke,et al.  Exocytotic Ca2+ channels in mammalian central neurons , 1995, Trends in Neurosciences.

[51]  R. Macdonald,et al.  Antiepileptic Drug Mechanisms of Action , 1993, Epilepsia.

[52]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[53]  Y. Ben-Ari,et al.  GABA: an excitatory transmitter in early postnatal life , 1991, Trends in Neurosciences.

[54]  W Zieglgänsberger,et al.  Baclofen reduces post‐synaptic potentials of rat cortical neurones by an action other than its hyperpolarizing action. , 1987, The Journal of physiology.

[55]  I. Jolliffe.  Principal Component Analysis , 2005 .

[56]  R. Macdonald,et al.  Carbamazepine and 10,11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. , 1986, The Journal of pharmacology and experimental therapeutics.

[57]  L. Nowak,et al.  GABA and bicuculline actions on mouse spinal cord and cortical neurons in cell culture , 1982, Brain Research.

[58]  P. Slater,et al.  Effect of morphine on catecholamine‐stimulated cyclic AMP production in cortex slices from rats and mice , 1981, Journal of neuroscience research.